Literature DB >> 22467312

Endothelium-specific sepiapterin reductase deficiency in DOCA-salt hypertension.

Ji Youn Youn1, Ting Wang, John Blair, Karine M Laude, Jeong-Ho Oak, Louise A McCann, David G Harrison, Hua Cai.   

Abstract

The endothelial nitric oxide synthase (eNOS) requires tetrahydrobiopterin (H(4)B) as a cofactor and, in its absence, produces superoxide (O(2)(·-)) rather than nitric oxide (NO(·)), a condition referred to as eNOS uncoupling. DOCA-salt-induced hypertension is associated with H(4)B oxidation and uncoupling of eNOS. The present study investigated whether administration of sepiapterin or H(4)B recouples eNOS in DOCA-salt hypertension. Bioavailable NO(·) detected by electron spin resonance was markedly reduced in aortas of DOCA-salt hypertensive mice. Preincubation with sepiapterin (10 μmol/l for 30 min) failed to improve NO(·) bioavailability in hypertensive aortas while it augmented NO(·) production from control vessels, implicating a hypertension-associated deficiency in sepiapterin reductase (SPR), the rate-limiting enzyme for sepiapterin conversion to H(4)B. Indeed, a decreased SPR expression was observed in aortic endothelial cells, but not in endothelium-denuded aortic remains, implicating an endothelium-specific SPR deficiency. Administration of hypertensive aortas with H(4)B (10 μmol/l, 30 min) partially restored vascular NO(·) production. Combined administration of H(4)B and the NADPH oxidase inhibitor apocynin (100 μmol/l, 30 min) fully restored NO(·) bioavailability while reducing O(2)(·-) production. In angiotensin II-induced hypertension, however, aortic endothelial SPR expression was not affected. In summary, administration of sepiapterin is not effective in recoupling eNOS in DOCA-salt hypertension, due to an endothelium-specific loss in SPR, whereas coadministration of H(4)B and apocynin is highly efficient in recoupling eNOS. This is consistent with our previous observations that in angiotensin II hypertension, endothelial deficiency in dihydrofolate reductase is alternatively responsible for uncoupling of eNOS. Taken together, these data indicate that strategies specifically targeting at different H(4)B metabolic enzymes might be necessary in restoring eNOS function in different types of hypertension.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22467312      PMCID: PMC3378300          DOI: 10.1152/ajpheart.00835.2011

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  33 in total

1.  Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin.

Authors:  J B Laursen; M Somers; S Kurz; L McCann; A Warnholtz; B A Freeman; M Tarpey; T Fukai; D G Harrison
Journal:  Circulation       Date:  2001-03-06       Impact factor: 29.690

2.  Effect of vitamin C on the availability of tetrahydrobiopterin in human endothelial cells.

Authors:  T A Baker; S Milstien; Z S Katusic
Journal:  J Cardiovasc Pharmacol       Date:  2001-03       Impact factor: 3.105

Review 3.  Tetrahydrobiopterin biosynthesis, utilization and pharmacological effects.

Authors:  G Werner-Felmayer; G Golderer; E R Werner
Journal:  Curr Drug Metab       Date:  2002-04       Impact factor: 3.731

4.  Induction of endothelial NO synthase by hydrogen peroxide via a Ca(2+)/calmodulin-dependent protein kinase II/janus kinase 2-dependent pathway.

Authors:  H Cai; M E Davis; G R Drummond; D G Harrison
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-10       Impact factor: 8.311

5.  Endothelial dysfunction of coronary resistance arteries is improved by tetrahydrobiopterin in atherosclerosis.

Authors:  C P Tiefenbacher; T Bleeke; C Vahl; K Amann; A Vogt; W Kübler
Journal:  Circulation       Date:  2000-10-31       Impact factor: 29.690

6.  Role of uncoupled endothelial nitric oxide synthase in abdominal aortic aneurysm formation: treatment with folic acid.

Authors:  Ling Gao; Kin L Siu; Karel Chalupsky; Andrew Nguyen; Peng Chen; Neal L Weintraub; Zorina Galis; Hua Cai
Journal:  Hypertension       Date:  2011-11-14       Impact factor: 10.190

7.  Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression by hydrogen peroxide.

Authors:  G R Drummond; H Cai; M E Davis; S Ramasamy; D G Harrison
Journal:  Circ Res       Date:  2000-02-18       Impact factor: 17.367

8.  Cellular basis of endothelial dysfunction in small mesenteric arteries from spontaneously diabetic (db/db -/-) mice: role of decreased tetrahydrobiopterin bioavailability.

Authors:  Malarvannan Pannirselvam; Subodh Verma; Todd J Anderson; Chris R Triggle
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

Review 9.  Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress.

Authors:  H Cai; D G Harrison
Journal:  Circ Res       Date:  2000-11-10       Impact factor: 17.367

10.  The ratio between tetrahydrobiopterin and oxidized tetrahydrobiopterin analogues controls superoxide release from endothelial nitric oxide synthase: an EPR spin trapping study.

Authors:  Jeannette Vásquez-Vivar; Pavel Martásek; Jennifer Whitsett; Joy Joseph; Balaraman Kalyanaraman
Journal:  Biochem J       Date:  2002-03-15       Impact factor: 3.857

View more
  11 in total

1.  Bone Morphogenic Protein 4 Mediates NOX1-Dependent eNOS Uncoupling, Endothelial Dysfunction, and COX2 Induction in Type 2 Diabetes Mellitus.

Authors:  Ji-Youn Youn; Jun Zhou; Hua Cai
Journal:  Mol Endocrinol       Date:  2015-06-29

Review 2.  NADPH oxidases and oxidase crosstalk in cardiovascular diseases: novel therapeutic targets.

Authors:  Yixuan Zhang; Priya Murugesan; Kai Huang; Hua Cai
Journal:  Nat Rev Cardiol       Date:  2019-10-07       Impact factor: 32.419

3.  The Role of Hypoxia-Inducible Factor/Prolyl Hydroxylation Pathway in Deoxycorticosterone Acetate/Salt Hypertension in the Rat.

Authors:  Mohammad K Dallatu; Elizabeth Nwokocha; Ngozi Agu; Choi Myung; Mohammad A Newaz; Gabriela Garcia; Luan D Truong; Adebayo O Oyekan
Journal:  J Hypertens (Los Angel)       Date:  2014-12

Review 4.  Mechanisms and consequences of endothelial nitric oxide synthase dysfunction in hypertension.

Authors:  Qiang Li; Ji-Youn Youn; Hua Cai
Journal:  J Hypertens       Date:  2015-06       Impact factor: 4.844

5.  Sepiapterin reductase gene-disrupted mice suffer from hypertension with fluctuation and bradycardia.

Authors:  Chiho Sumi-Ichinose; Yui Suganuma; Taiki Kano; Noriko Ihira; Hiroko Nomura; Kazuhisa Ikemoto; Tadayoshi Hata; Setsuko Katoh; Hiroshi Ichinose; Kazunao Kondo
Journal:  Physiol Rep       Date:  2017-03

6.  Roles for endothelial cell and macrophage Gch1 and tetrahydrobiopterin in atherosclerosis progression.

Authors:  Gillian Douglas; Ashley B Hale; Jyoti Patel; Surawee Chuaiphichai; Ayman Al Haj Zen; Victoria S Rashbrook; Lucy Trelfa; Mark J Crabtree; Eileen McNeill; Keith M Channon
Journal:  Cardiovasc Res       Date:  2018-08-01       Impact factor: 10.787

Review 7.  Tetrahydrobiopterin in cardiovascular health and disease.

Authors:  Jennifer K Bendall; Gillian Douglas; Eileen McNeill; Keith M Channon; Mark J Crabtree
Journal:  Antioxid Redox Signal       Date:  2014-03-14       Impact factor: 8.401

8.  Cell-autonomous role of endothelial GTP cyclohydrolase 1 and tetrahydrobiopterin in blood pressure regulation.

Authors:  Surawee Chuaiphichai; Eileen McNeill; Gillian Douglas; Mark J Crabtree; Jennifer K Bendall; Ashley B Hale; Nicholas J Alp; Keith M Channon
Journal:  Hypertension       Date:  2014-04-28       Impact factor: 10.190

9.  Toll-Like Receptor 2 (TLR2) Knockout Abrogates Diabetic and Obese Phenotypes While Restoring Endothelial Function via Inhibition of NOX1.

Authors:  Zhen Guo; Yixuan Zhang; Chang Liu; Ji Youn Youn; Hua Cai
Journal:  Diabetes       Date:  2021-06-14       Impact factor: 9.337

10.  Dual role of endothelial nitric oxide synthase in oxidized LDL-induced, p66Shc-mediated oxidative stress in cultured human endothelial cells.

Authors:  Yi Shi; Thomas F Lüscher; Giovanni G Camici
Journal:  PLoS One       Date:  2014-09-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.